ImmunityBio Class Action Lawsuit Opens for Potential Lead Plaintiffs Amid Stock Price Drop

ImmunityBio Faces Class Action Lawsuit Following Stock Decline

Background
The legal landscape surrounding ImmunityBio, Inc. (NASDAQ: IBRX) has become increasingly tumultuous after the law firm Robbins Geller Rudman & Dowd LLP announced the opportunity for investors who faced substantial losses to lead a securities class action lawsuit. This development comes after a significant drop in the company's stock, coinciding with troubling allegations regarding its flagship product, Anktiva.

Important Dates
Investors who purchased shares of ImmunityBio between January 19, 2026, and March 24, 2026, have until May 26, 2026, to seek the appointment as lead plaintiff in this class action lawsuit known as Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.). This window provides a critical opportunity for injured investors to act against the perceived mismanagement and inaccuracies within the firm.

Allegations Against ImmunityBio
The class action lawsuit alleges that statements made by the defendants violated the Securities Exchange Act of 1934. It primarily charges that there were false or misleading claims regarding Anktiva’s capabilities, specifically asserting that it would ensure long-term cancer-free status for all patients treated—an assertion that has not been adequately demonstrated.

Furthermore, the allegations include accusations that the description of Anktiva as a cancer vaccine was misleading, with the claims made by Dr. Patrick Soon-Shiong, ImmunityBio's Executive Chairman and Global Scientific and Medical Officer, overstating the product’s potential.

A pivotal moment in the case was reached when a warning letter from the U.S. Food and Drug Administration (FDA) dated March 13, 2026, was made public. The letter highlighted violations concerning misleading advertisements related to Anktiva, stating that promotional materials may have created unfounded expectations regarding the treatment's efficacy against all forms of cancer. This announcement reportedly triggered a 21% drop in ImmunityBio’s stock price, exacerbating losses for investors.

Lead Plaintiff Process
The Private Securities Litigation Reform Act of 1995 empowers any individual who purchased ImmunityBio’s publicly traded securities during the class period to consider becoming the lead plaintiff in the case. The lead plaintiff’s role will be to represent the interests of all class members in this legal endeavor, also allowing them to select their legal counsel. Moreover, involvement in this capacity does not limit an investor's potential recovery from damages resulting from the situation.

About Robbins Geller
Robbins Geller Rudman & Dowd LLP is a preeminent firm specializing in securities fraud and shareholder rights litigation. The firm has garnered acclaim as a top law firm in the realm of class action recoveries, having secured over $916 million for investors in 2025 alone and totaling $8.4 billion over the past five years. With a team of around 200 lawyers distributed across 10 offices, Robbins Geller has been pivotal in various high-stakes cases, including historically significant recoveries in securities class action lawsuits.

Conclusion
For investors feeling the effects of ImmunityBio’s stock plummet and uncertain future, this class action lawsuit presents a viable avenue for seeking justice and potential compensation. As new developments unfold, affected individuals are urged to consider their options closely, especially with approaching deadlines and the intricacies of their investor rights now coming into focus. If you wish to pursue this opportunity and possibly serve as the lead plaintiff, you can reach out to attorneys Ken Dolitsky or Michael Albert at Robbins Geller for guidance on the next steps.